Doctors don’t have a single definitive test that says “this patient is in stage 2 dementia” the way a blood glucose test definitively measures diabetes. Instead, they piece together a diagnosis by combining cognitive assessments, brain imaging, medical history, and observations of how a person functions in daily life. This approach exists because dementia is a complex condition—it damages the brain in different ways across different people, and no single measurement captures that complexity. When a doctor stages dementia, they’re drawing on tests that measure memory loss, thinking speed, language ability, and judgment, alongside physical exams and sometimes brain scans.
A patient might score low on a memory test but perform well on a language assessment. Brain imaging might show shrinkage in specific regions, while blood work rules out other causes of cognitive decline. The doctor synthesizes all this information to determine whether someone is in mild (early-stage), moderate (middle-stage), or severe (late-stage) dementia. This multi-tool approach has a practical consequence: two neurologists might stage the same patient slightly differently, or a patient’s stage might shift based on which test a doctor emphasizes. Understanding how these assessments work—and their limits—helps families grasp why doctors sometimes give cautious or qualified answers about prognosis.
Table of Contents
- Why Doctors Need Multiple Tools to Assess Dementia
- The Assessment Tools Doctors Use Most Often
- How Brain Imaging Fits Into Staging
- How Cognitive Test Scores Map to Dementia Stages
- The Role of Medical History and Other Causes
- Why the Same Patient Gets Different Stage Assessments
- How Family Input Shapes Accurate Staging
- Frequently Asked Questions
Why Doctors Need Multiple Tools to Assess Dementia
The brain is too complex to reduce to one number. dementia attacks different cognitive systems at different rates depending on the underlying disease. Alzheimer’s disease typically begins by eroding memory and spatial awareness but may spare language early on, whereas frontotemporal dementia often starts by damaging personality and judgment while leaving memory intact for longer. A test designed to catch memory loss early won’t reliably detect frontotemporal dementia, just as a language test alone misses pure memory problems. Another reason for multiple assessments is that test performance fluctuates. A patient might score better on a cognitive test after a good night’s sleep, worse during a medication adjustment, or differently in a quiet clinic room versus a noisy waiting room.
Depression, untreated hearing loss, or poor vision can artificially lower scores without indicating dementia progression. By using multiple tests over time, doctors filter out these temporary variations and spot genuine cognitive decline. Staging also requires understanding how a person’s cognitive changes translate to real-world function. Someone might fail a word-list memorization test but still manage finances, cook meals, and recognize family members. Another person might pass the same test but get lost at home or repeat the same question every five minutes. Staging isn’t just about test scores—it’s about how much cognitive loss has actually disrupted the person’s ability to live.
The Assessment Tools Doctors Use Most Often
The Montreal Cognitive Assessment (MoCA) is one of the most common office-based tests. It takes 10 to 15 minutes and covers memory, language, spatial awareness, attention, and executive function (planning and reasoning). A person copies a clock, recalls a word list, names objects, and follows instructions. Doctors often repeat the MoCA every 6 to 12 months to track whether cognitive decline is happening and how fast. However, education level and language fluency heavily influence MoCA scores—a non-native English speaker or someone with minimal schooling might score lower even with no actual dementia. The Mini-Cog is shorter and is often used in primary-care offices. It combines a three-word recall test with drawing a clock face and takes about three minutes.
It’s useful as a screening tool but too brief to guide detailed staging—a low Mini-Cog score prompts referral for more thorough testing, not a diagnosis on its own. The advantage is that it’s fast and can catch missed cognitive decline during a routine office visit. The disadvantage is that it misses the nuanced picture that longer assessments provide. Neuropsychological testing is the gold standard when specialists need detailed staging. A trained psychologist administers two to four hours of tests measuring memory (immediate and delayed), attention, language, spatial skills, and executive function. This depth allows doctors to map which cognitive domains are impaired and which are preserved, which helps pinpoint the underlying disease and rule out mimics like depression or medication side effects. The trade-off is cost, time, and that the person being tested must be well enough to sit through a long session.
How Brain Imaging Fits Into Staging
MRI scans can show structural changes—brain shrinkage in specific regions, or small-vessel disease affecting white matter (the “wiring” connecting brain regions). An MRI revealing marked atrophy in the hippocampus (key for memory) supports an Alzheimer’s diagnosis and suggests more advanced disease. However, brain shrinkage isn’t unique to dementia; some occurs with normal aging, and it doesn’t correlate perfectly with cognitive decline. A person with significant atrophy on MRI might function well, while someone with minimal atrophy might have severe symptoms. PET imaging is less commonly done in routine practice but provides earlier warning signs. Amyloid PET detects amyloid protein deposits in the brain, which accumulate years before memory problems appear.
Tau PET shows tau tangles, another hallmark Alzheimer’s pathology. These scans help specialists identify people in very early disease stages and can guide treatment decisions (some new medications only work in early symptomatic or presymptomatic disease). The limitation is that amyloid and tau can be present without causing symptoms, making it difficult to distinguish who will decline versus who will remain stable. Blood biomarkers—phosphorylated tau and phosphorylated tau217—are emerging tools that can detect Alzheimer’s pathology without brain imaging. A simple blood draw, not an expensive scan, is starting to replace PET in some clinics. But these biomarkers are still being validated in routine practice, and not all doctors have access to reliable testing yet.
How Cognitive Test Scores Map to Dementia Stages
Most doctors use a framework where mild-stage dementia means the person still handles most daily tasks, moderate means they need increasing help with complex tasks, and severe means they depend on others for basic needs like eating and toileting. Cognitive tests provide one piece of this puzzle. Someone who scores 20 out of 30 on the MoCA typically has mild impairment, while a score of 10 might suggest moderate or severe impairment. But the mapping isn’t automatic—a score of 15 could be early or middle-stage depending on the person’s baseline and how rapidly they’re declining. The Clinical Dementia Rating (CDR) scale asks a caregiver or family member about the person’s memory, orientation, judgment, and daily function. The CDR generates a score (0 = no dementia, 0.5 = questionable, 1 = mild, 2 = moderate, 3 = severe) and tracks decline over time. Many research studies and clinical centers use CDR staging as the standard.
Unlike a test score, the CDR captures what the person can actually do—whether they remember to take medications, whether they get lost in familiar places, whether they can manage money. A limitation is that it relies on a caregiver’s observations, and caregivers sometimes underestimate or overestimate problems. Functional assessment is the practical complement to cognitive scores. A person staging as mild might still work part-time, manage their own doctor appointments, and remember to pay bills. Someone staging as moderate often stops driving, forgets appointments, and needs reminders to shower. In severe stages, the person doesn’t recognize family members, doesn’t speak in full sentences, and can’t eat without help. Doctors ask caregivers “Can they still cook?” “Do they get lost at home?” “Do they know the year?” to anchor cognitive scores in real-world impact.
The Role of Medical History and Other Causes
Before staging dementia, doctors must rule out reversible causes that mimic dementia: untreated thyroid disease, vitamin B12 deficiency, severe depression, normal-pressure hydrocephalus, or medication side effects. A patient presenting with memory loss might be hypothyroid; fixing the thyroid resolves the cognitive problems. These conditions can coexist with dementia, muddying the picture. A person with both Alzheimer’s and an untreated thyroid condition might appear more impaired than they would if the thyroid were treated. Blood tests, thyroid panels, and sometimes brain imaging are part of the workup.
A doctor who skips this step risks misidentifying a reversible condition as irreversible dementia—and missing the chance to help. Conversely, extensive testing can delay a diagnosis in someone with clear-cut dementia and no red flags for reversible causes. The doctor’s judgment about when to test extensively versus when to proceed with a diagnosis is part of what makes staging an art as well as a science. Comorbid conditions like stroke history, Parkinson’s disease, or major depression also influence staging. Someone with both Parkinson’s disease and Alzheimer’s is more impaired than either disease alone, and the staging may emphasize movement problems and mood alongside memory loss. A person with severe depression can score poorly on cognitive tests without having dementia; depression can resolve with treatment, improving test scores, while dementia does not.
Why the Same Patient Gets Different Stage Assessments
A patient may be staged as mild dementia by one doctor based on MoCA scores, but as early-moderate by another based on functional decline reported by a caregiver. This isn’t necessarily an error—it reflects that staging exists on a spectrum, not in discrete boxes. The two doctors might both be correct, just emphasizing different evidence.
Another source of variation is timing and setting. A patient tested early in the day, well-rested and well-fed, may score higher than the same person tested after a day of appointments and fatigue. A patient with social anxiety may perform worse in a formal clinic than in a familiar home environment. Serial testing—assessing the person multiple times over months—smooths out these variations and gives a clearer picture of true decline.
How Family Input Shapes Accurate Staging
Doctors rely on family observations because they spend far more time with the patient than any clinician does. A spouse notices when the person stopped remembering to pay bills or started repeating the same story three times in an hour. Adult children spot that a parent who used to research major purchases now can’t follow a restaurant menu or recall yesterday’s conversation. These observations inform the CDR score and the doctor’s judgment about functional stage. Without reliable input from someone close to the patient, staging becomes less accurate.
Families should come prepared to specific questions: “When did you first notice changes?” “What tasks has your loved one stopped doing?” “Do they get lost? Forget medications? Withdraw from activities they enjoyed?” Specific examples—not just “memory is declining”—help the doctor assess severity accurately. A family saying “Mom repeats questions constantly and can’t follow TV shows anymore” conveys more useful information than “Mom’s memory isn’t good.” The relationship between doctor and family also matters. If a family downplays symptoms out of denial, or exaggerates them out of stress, the staging can shift. Some doctors encourage families to keep a simple log over several weeks—what tasks the person managed, what they forgot, instances of confusion—before the next appointment. This objective record reduces guesswork and provides a clearer baseline for tracking change.
- —
Frequently Asked Questions
If my parent scores well on the MoCA but I see clear memory problems at home, which is more accurate?
Both observations are valid and suggest you should discuss this gap with the doctor. Office performance doesn’t always match real-world function. The doctor may recommend longer neuropsychological testing or a repeat assessment, since early dementia can be mild enough that a brief test misses it.
Can dementia be accurately staged with only a blood test or brain scan, without cognitive testing?
No. Blood biomarkers and scans show whether disease pathology is present, but not how much cognitive impact it has. Staging requires understanding both the brain damage and how much the person’s thinking and daily function are affected.
How often should dementia staging be reassessed?
Most doctors reassess every 6 to 12 months with repeat cognitive testing or CDR scores. More frequent assessment (every 3 months) may be needed if the person is declining rapidly or if a new medication is being tried. Some patients are stable for years; others decline noticeably in a few months.
Does staging stay the same, or can someone move backward (improve)?
Dementia is progressive, so staged decline is the expected pattern. However, a patient’s apparent stage can improve if a reversible cause (like a medication side effect or thyroid disease) is treated. The underlying dementia doesn’t reverse, but reducing other contributors to cognitive impairment can improve function.
What if my doctor says my loved one is “borderline mild dementia”—what does that mean?
Borderline dementia (sometimes called mild cognitive impairment or MCI) means cognitive decline beyond normal aging but not yet severe enough to significantly impair daily life. It suggests increased risk of progression to dementia, but not everyone with MCI develops dementia. Close monitoring and repeat testing help clarify whether decline is progressing or stable.
Can two doctors disagree on dementia stage and both be right?
Yes. Staging is partly objective (test scores) and partly subjective (interpreting what those scores mean, weighing functional reports from caregivers, considering the patient’s baseline). Two competent doctors might stage someone as mild versus early-moderate based on different weightings of the same evidence.
